3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Gastrointestinal
3
Thoracic
2
Head & Neck
2
Sarcoma
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Sarcoma
2
Mesothelioma, Malignant
2
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Neoplasm Metastasis
1
MSI-H Colorectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Anus Neoplasms
1
Advanced Refractory Solid Tumors
1
Interventions
pembrolizumab
10
Nivolumab
5
Granulocyte Colony-Stimulating Factor
4
atezolizumab
3
Ipilimumab
3
Ifosfamide
3
Etoposide
3
tislelizumab
2
sargramostim
2
durvalumab
2
Thiotepa
2
Paclitaxel
2
Mesna
2
Melphalan
2
Filgrastim
2
Docetaxel
2
Cyclophosphamide
2
Carboplatin
2
Busulfan
2
tazemetostat
1
spartalizumab
1
regorafenib
1
pegylated granulocyte colony-stimulating factor
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
etoposide phosphate
1
epacadostat
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
regorafenib
×
Other solid neoplasm
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled